A randomized phase III study compared capecitabine versus either lapatinib or pyrotinib in patients with HER2-positive breast cancer or metastatic breast cancer who previously received trastuzumab, taxanes, and/or anthracyclines. Here, ERBB2 is linked to breast carcinoma.